NASDAQ · ABSI

Absci Corporation

Healthcare · Biotechnology

$8.24▼ 4.74% ($0.41)at close

After hours$8.21▼ 0.41%7:40 PM ET

52-week

$2.24$12.06

Market cap

$1.40B

P/E

-10.30

Volume

3.08M

Shares outstanding

169.40M

What the market price implies · Reverse DCF

Historical revenue grew by -12.52%/yr over the past 4 years.

Selected forecast · Base scenario

0.8%/yr · actual 10-year annualized revenue growth

Year 1 growth: 0%

Market-implied · Base operating assumptions + edited margins

Unavailable · flat 10-year annualized revenue growth

Reverse DCF solves revenue growth itself using Base operating assumptions and your edited margins. Changing forecast growth alone does not change the implied rate. This is a model-implied requirement, not an analyst forecast.

No supported revenue growth rate matches this price with these operating assumptions.

Valuation

Recommended · Revenue & margin DCF

Price used

$8.24

Estimated value / share

Unavailable

Base scenario

USD · TTM ending 2026-06-30

Every projected year produces negative free cash flow, so the model returns a negative enterprise value. A discounted-cash-flow valuation cannot be defended on those inputs, so it is not shown.

Reported operating earnings and the comparable cash-flow estimate differ substantially; the model retains the reported-margin anchor.

Year 1 growth 0% · Ending margin 0% · Discount rate 18.35%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 10, 2026, 8:00 PM UTC
Financial statement period: TTM ending 2026-06-30
Data refreshed: Sep 11, 2026, 2:44 AM UTC · provider

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Price vs Fundamentals

Why The Stock Is Moving

Mixed / unclearLow confidence

1Y Price: 246.22%Revenue (TTM): -62.28%FCF (TTM): -42.03%

What changed

The stock rose 246.22% over the last year. Revenue declined 62.28% over the trailing twelve months. Operating margin moved from -2,846.57% to -8,411.27%. Free cash flow declined 42.03% over the trailing twelve months.

What the market seems to be pricing

The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.

What would invalidate this read

Operating margin currently stands at -8,411.27%. A decisive move in revenue — currently down 62.28% — would be the clearest signal to resolve the ambiguity.

Performance

Return analysis

Company profile

Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds.

CEOSean McClain

SectorHealthcare

IndustryBiotechnology

Employees140

IPO dateJul 22, 2021

https://www.absci.com

Market multiples

Forward P/E—

EV/EBITDA-4.48

Enterprise value$462.63M

Stock splits

No stock splits recorded for this ticker.

Profitability & growth

Revenue growth-46.37%

Gross margin-255.93%▲958.2ppvs FY2024

Operating margin-8,411.27%▼2052.6ppvs FY2024

ROE-57.72%▲4.8ppvs FY2025

Analyst consensus

RatingBuy

Target price$13.60▲65.05%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 16, 2026

Q4 FY26 · EPS est -$0.19 · Revenue est $697.57K

View